Phosphodiesterase inhibitors in the management of primary pulmonary hypertension

Prog Cardiovasc Nurs. 2004 Spring;19(2):74-9. doi: 10.1111/j.0889-7204.2004.02898.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Calcium Channel Blockers / pharmacology
  • Calcium Channel Blockers / therapeutic use
  • Drug Therapy, Combination
  • Endothelins / antagonists & inhibitors
  • Epoprostenol / analogs & derivatives
  • Humans
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / physiopathology
  • Patient Selection
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Purines
  • Sildenafil Citrate
  • Sulfones
  • Treatment Outcome
  • Vasodilator Agents / pharmacology
  • Vasodilator Agents / therapeutic use

Substances

  • Calcium Channel Blockers
  • Endothelins
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate
  • Epoprostenol